---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-262125"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:08:30.177539+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma reports positive Phase 3 TANDEM topline data; FDC lowers LDL-C 48.6% vs placebo

## Summary
- Fixed-dose combination of obicetrapib 10 mg and ezetimibe 10 mg achieved LS mean LDL-C reduction of 48.6% (p<0.0001) vs placebo at day 84.
- All co-primary endpoints met with statistical significance; FDC superior to both monotherapies (p<0.001).
- Over 60% of FDC patients saw >50% LDL-C reduction; ~71% achieved LDL-C <55 mg/dL.
- Safety well-tolerated; drug-related TEAEs 2.9% in FDC arm vs 3.9% placebo; no serious TEAEs.
- Data supports global regulatory filings for the FDC tablet.

## SEC filing metadata
- accession: 0001193125-24-262125
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524262125/0001193125-24-262125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524262125/d868860d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-262125
- JSON: https://secwatch.observer/filing/0001193125-24-262125.json
- Plain text: https://secwatch.observer/filing/0001193125-24-262125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.